Microbot Medical announced that its Liberty endovascular robotic system is now commercially available in the U.S.

Liberty is the first U.S. Food and Drug Administration (FDA)-cleared single-use, remotely operated robotic system for peripheral endovascular procedures. It won this FDA nod in September 2025.

The limited market release will introduce Liberty to select, high procedure volume regions where preliminary demand for Liberty has already occurred. The release will focus on gathering real-world insights from possible high-volume users—expected full market release is expected during the Society of Interventional Radiology (SIR) conference in April 2026.

Since obtaining the FDA 510(k) clearance for Liberty, Microbot Medical has secured a third-party logistics partner and is expanding its commercial leadership team to ensure a supported and successful limited market release.

“We are excited to enter the commercialization phase of LIBERTY. We are building a new robotic category with the introduction of LIBERTY, the world’s first single-use robotic system,” said Harel Gadot, chairman, president, and CEO of Microbot Medical. “Launching just weeks after announcing FDA clearance, we believe that we have demonstrated the strength of our team and the unique innovation behind LIBERTY. Building on the strong interest and feedback we have received so far from physicians and hospital administrators, the limited market release is expected to enable us to responsibly support early adopters and lay the groundwork for a full market launch at the Society of Interventional Radiology meeting in April.”

Earlier this week, the company was awarded its first Japanese patent for core Liberty technology, such as a compact robotic device for driving and manipulating the movement of at least one elongate surgical tool.